Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegerion Pharmaceuticals, a Massachusetts-based emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, has appointed Martha Carter to its executive team as chief regulatory officer (CRO).
Subscribe to our email newsletter
Carter was most recently Proteon Therapeutics senior vice president and CRO where she was responsible for the company’s worldwide regulatory and quality functions.
Prior to this, she was Trine Pharmaceuticals senior vice president of Regulatory Affairs which was preceded by her tenure as GelTex Pharmaceuticals vice president of Regulatory Affairs.
In the latter role, she led the company’s regulatory and quality control functions for both commercial and investigational drug products.
Aegerion CEO Marc Beer said Carter brings over 30 years of regulatory and quality assurance experience to Aegerion, and her success with approval for drugs such as Neumega, WelChol, and Renagel bolsters Aegerion’s confidence to file for the NDA and MAA filings for lomitapide.